1. Herz JM., Buated W., Thomsen W., Mori Y. (2020) Novel TRPA1 antagonists are multimodal blockers of human TRPA1 channels: Drug candidates for treatment of familial episodic pain syndrome (FEPS). FASEB J 34:S1-1.

2. Desclaux S., Sriwatananukulkit O., Buated W., Himakhum W., Herz JM., Hemstapat R. (2020) ALGX-XC20, a novel transient receptor potential ankyrin 1 (TRPA1) antagonist attenuates joint pain and articular cartilage damage in an osteoarthritis rat model. FASEB J 34:S1-1.

3. Herz JM., Kesicki E., Tian J., Zhu M., Thomsen J. (2016) A novel class of potent, allosteric TRPA1 antagonists reverse hyperalgesia in multiple rat models of chronic pain. FASEB J 30: 927.3

4. Paulsen CE., Amache JP., Gao Y., Cheng Y., Julius D. (2015) Structure of the TRPA1 ion channel suggests regulatory mechanisms. Nature 520: 511-517.

5. Andrade EL., Meotti FC., Calixto JB. (2012) TRPA1 antagonists as potential analgesic drugs. Pharmacol Ther 133:189-204. Provides a review of TRPA1 antagonists for different types of pain.

6. Binder A., May D., Baron R., Maier C., Tölle TR., et al. (2011) Transient receptor potential channel polymorphisms are associated with the somatosensory function in neuropathic pain patients. PLoS One 6(3):e17387.

7. Kremeyer B., Lopera F., Cox JJ., Momin A., Rugiero F., Marsh S., Woods CG., Paterson KJ., Fricker FR., Villegas A., et al. (2010) A gain-of-function mutation in TRPA1 causes familial episodic pain syndrome. Neuron 66: 671-680.

8. Opioids as Drugs of Abuse.

9. Opioid Overdose Crisis.